Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Celldex Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 229 | 2 | 253 | +26 |
| Shares | 72.6M | 26.2K | 85.0M | +12.5M (+17.2%) |
| Value | $2.31B | $830.9K | $3.16B | +$850.9M (+36.8%) |
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (47)
Institutions that held Celldex Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (21)
Institutions that held Celldex Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Vestal Point Capital, LP | 1,224,165 | $38.8M |
| Citadel Advisors LLC | 200,612 | $6.36M |
| Silverarc Capital Management, LLC | 178,378 | $5.66M |
| Jane Street Group, LLC | 90,321 | $2.86M |
| Tudor Investment Corp Et Al | 35,393 | $1.12M |
| ArrowMark Colorado Holdings LLC | 25,000 | $793.0K |
| Virtu Financial LLC | 19,830 | $629.0K |
| Marex Group plc | 12,000 | $380.6K |
| Twinbeech Capital LP | 11,445 | $363.0K |
| Scientech Research LLC | 9,502 | $301.4K |
| Walleye Capital LLC | 8,147 | $258.4K |
| Jain Global LLC | 7,763 | $246.2K |
| EntryPoint Capital, LLC | 7,430 | $235.7K |
| Axq Capital, LP | 7,237 | $229.6K |
| Advisory Services Network, LLC | 4,625 | $146.7K |
| Sound Income Strategies, LLC | 454 | $14.2K |
| Innovative Asset Advisors Group, LLC | 200 | $6.34K |
| Quadrant Capital Group LLC | 160 | $5.08K |
| Twin Peaks Wealth Advisors, LLC | 46 | $1.46K |
| MAI Capital Management | 8 | $254 |
| Scarborough Advisors, LLC | 6 | $190 |
Not filed for Q2 2026 yet (2)
Institutions that held Celldex Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 25,642 | $813.6K |
| CWM, LLC | 544 | $17.3K |